Puma Biotechnology, Inc. (PBYI)
NASDAQ: PBYI · Real-Time Price · USD
2.750
-0.030 (-1.08%)
Dec 20, 2024, 4:00 PM EST - Market closed
Puma Biotechnology Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Puma Biotechnology stock has a target of 7.00, which predicts an increase of 154.55% from the current stock price of 2.75.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 20, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for PBYI is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +154.55% | Nov 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +154.55% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +154.55% | Aug 2, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +154.55% | Jul 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +154.55% | Jun 4, 2024 |
Financial Forecast
Revenue This Year
228.41M
from 235.64M
Decreased by -3.07%
Revenue Next Year
212.06M
from 228.41M
Decreased by -7.16%
EPS This Year
0.31
from 0.45
Decreased by -31.93%
EPS Next Year
0.35
from 0.31
Increased by 13.10%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 235.8M | 244.3M | 261.7M | |||
| Avg | 228.4M | 212.1M | 210.9M | |||
| Low | 218.7M | 177.4M | 162.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 0.1% | 7.0% | 23.4% | |||
| Avg | -3.1% | -7.2% | -0.6% | |||
| Low | -7.2% | -22.3% | -23.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 0.34 | 0.59 | 0.89 | |||
| Avg | 0.31 | 0.35 | 0.32 | |||
| Low | 0.27 | 0.20 | -0.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -25.3% | 91.9% | 157.6% | |||
| Avg | -31.9% | 13.1% | -8.7% | |||
| Low | -41.0% | -33.1% | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.